{"name":"Mundipharma Medical Company","slug":"mundipharma-medical-company","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Metabolic","slug":"metabolic","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Sevre-Long™","genericName":"Sevre-Long™","slug":"sevre-long","indication":"Type 2 diabetes","status":"phase_3"}]}],"pipeline":[{"name":"Sevre-Long™","genericName":"Sevre-Long™","slug":"sevre-long","phase":"phase_3","mechanism":"Sevre-Long™ is a glucagon-like peptide-1 (GLP-1) receptor agonist that mimics the action of the incretin hormone GLP-1 to regulate glucose metabolism.","indications":["Type 2 diabetes","Obesity"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiW0FVX3lxTE13d0Y1OGNyZUdSMVUwVktfRkliOER6SzVVM3lQbXlGM3dPVWhUc3JMZ3ZabzJaZXNsVjNVRnlZVXpzSVgta2dkSGhOSjRESTIwYTB4OWoyUjN2TTg?oc=5","date":"2026-02-26","type":"pipeline","source":"Britannica","summary":"Sackler family | Brothers, OxyContin, Purdue Pharma, Opioid Epidemic, & Mundipharma - Britannica","headline":"Sackler family | Brothers, OxyContin, Purdue Pharma, Opioid Epidemic, & Mundipharma","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi8gFBVV95cUxQYzJIOHlGUEVwZ3hFTFM1ZjNUUml6aklWRWpaWUR4aVl6UWljVnlONWtOZTZkTTFEV2Q4Um5zLXdLa0NObk5faHNYMTNqZERsT2M2aXJrNHFpTkJseUJLdU55ZVd6MXZWTWdSWTcyb3VtX2FRal92Tk41YWhtcTBkMGNSVUJBbEtjNHgwMXZ0Tjh3ajEwYXlqZEg2YUxycmFFU1hVaUhwZHBXWlV4OG9FcGh4MFNsTlB4cEhLYnBsel9Nc2IyMGRfRTR2eEZ1YXRoODlvNU1FdlcwcGl3RS1oYjlCMHZPV2kwV1BHeUZtMVpxZw?oc=5","date":"2025-10-11","type":"trial","source":"Business Wire India","summary":"Mundipharma announces patient enrolment completion in Phase III ReSPECT clinical trial for REZZAYO® (rezafungin) - Business Wire India","headline":"Mundipharma announces patient enrolment completion in Phase III ReSPECT clinical trial for REZZAYO® (rezafungin)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi1gFBVV95cUxNNUpQMml2QW5rSFI5dnlORWl0UzhpMEgyOWJUWm8yS09KWUNubWpwVlQ3OVlvSk9fdFVpWWtUZ1RHaWlfVXVwRUpaWng5dDhzR3ZCTEVyTVJVRTlBeWlmYW1icXB0UW82dWhiTkhvT1BKcDVmRHE4TVItWTRNMFluU1MzN1ZPZnZDbjkxc3NsanZMbnRidkdLVzlIS281QzVnaGtabkJfb0RXN1pfbWtTRmNIb2lpYUtveEhpM29aOFUyMFN5emt6N0hNTTgxRTJXeGthRkZR0gHbAUFVX3lxTE9ZSm9kZzQ1aEJIdnluVUJsUk9VMkFZSjdEYXpISy1tSnRIcTRZUVUzWV9DR1IwODNkekZ6bzdoUUkzdm13dEhWalNhUjYzVnVxUmFpa09qM3JoU2FBRHVRejM0bXhtb3o2Uk1iNks0elZTUWw3dkdSOHdaZEdMVU9JNWw4OXllRjZtcWgwVW5ad1NGd2Q3ZDF6MGcxUlFTdTFGZC1BUjJCc3RxcEQ2ZUdYNTdLckMyZjlpWFl2dENNVURPZDlzWUxQSnRtR1phVDhxSXI2VkJXTHAxaw?oc=5","date":"2025-07-02","type":"pipeline","source":"Medical Dialogues","summary":"Delhi HC Rejects Modi-Mundipharma's Monopoly Claim Over 'CONTIN', Allows Limited Relief - Medical Dialogues","headline":"Delhi HC Rejects Modi-Mundipharma's Monopoly Claim Over 'CONTIN', Allows Limited Relief","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqAFBVV95cUxNSEkzTDNKTlhzSkM1R2k4dGpwQ3ptRVNab2hLU1NCRHNSTDljRVhWYkd5QlM0eGVPSDVPNXZaYVlMWGhqRnpWbkhZdFRfVmNYWndOVWtjczcwSmVmazZiZHdKbE5hTnI5dUt6UVFVY291UWlWUGd0ZTZGVTQtQ3NZUENkN1BzUmw3c2NtUmd4THZhZTk5ZERiRFpKWnZJWU9OQ0JMUmtva2M?oc=5","date":"2024-09-17","type":"pipeline","source":"The Washington Post","summary":"In the U.S., opioid-maker Purdue is bankrupt. Its global counterparts make millions. - The Washington Post","headline":"In the U.S., opioid-maker Purdue is bankrupt. Its global counterparts make millions.","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinwFBVV95cUxNTWo1M0NMT1pzY1pDcjN1SGJrTmZmcE8xWTZGMVlEUTlSUDU4TzVFUUNUSmx1WjNSRGQ5VWh5VGhQRERlLU5qWnlRRF9GVzkydUpkMldUOTFfZ1B2S0dtLXpfSVZUQmhjeDRWVE01c2pPMjlKVjRRNzJtR21FV1RhbmZTTjkwV05JVDg2VnhZamFlZVM3T3hKOEFnQ2dLTXc?oc=5","date":"2024-09-17","type":"earnings","source":"Finance Uncovered","summary":"Revealed: How the Sackler family’s opioid empire continues to make hundreds of millions of dollars in profits around the world - Finance Uncovered","headline":"Revealed: How the Sackler family’s opioid empire continues to make hundreds of millions of dollars in profits around the","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi1gFBVV95cUxObVBPV1J0MkZfWmM0TWFIWDgySDlRZ0RFUXd2OHhNN2tYMjE1cmpXYUhNa2ZYblU4N0pPUzZROTNCdEk0VjJjeDZZTElfY1BURHI4aERpSVlqaEpmT2RnUlkzZjBfdl96bFVTdFV0MEdmRHhiODA4cnFwWGc1QkQ2LXNNbWNMX2Y2amZZbGlPQ0JibWMyaEktdVhrQ0FvLUhIUlhMUmE1RDZCRllrVXJ2MW50a2hjcmtvbzk2clRfeWJwTXNod0J0YzhLOFI5WVFRSGNXS0hR?oc=5","date":"2024-08-28","type":"deal","source":"Reuters","summary":"Drugmaker Mundipharma's China unit sale fails to find buyer, sources say - Reuters","headline":"Drugmaker Mundipharma's China unit sale fails to find buyer, sources say","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTFBIQWJGUnRlX1VMRjBEd3B0SkNLMF83VEItQ0FIdUxmU2JDUHpKRUl0WVFKbEZ4UVVSMEhKSC1qdmFrZDFUZFV6Tk1pWVJwX3FmQWRyM1JXMkd5ZzhfWGt1OF8zbTFYdl9wWk5sSDRB0gFyQVVfeXFMUGhISG9weE1nSmdWNDZyZmF3b0xyTG5RdFVUSHVILTdZTGp0aU0wZ1pwaVZYVnpFOENNczNoZl81UmxxaEtaem1iWGV4SURUYzJRdWt3Y2xFdzdQazVEdElZaVZfR3ZXMEplcFJraVRuUGVn?oc=5","date":"2024-07-03","type":"pipeline","source":"koreabiomed.com","summary":"Samjin Pharm and Mundipharma Korea to co-promote Norspan patch - koreabiomed.com","headline":"Samjin Pharm and Mundipharma Korea to co-promote Norspan patch","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitAFBVV95cUxOS2NDYl9nRUZuY0tCVnI4NE9uNHVkZUltaDlPQktMN1FMdEQtcjRUVXQ1dW1KakRlbU1FTEppVmFZekVzRThfZ0R0bnFSQjAwT1dXeElIaGlMWTM0REhZUk9EUXRPd25xdEZ1Vl9xNHNaM1ZPcnV4VThMQk92bFo1ODB6V05fQjk0RU5NaGVaanpXSkN5dHAyaTFJNEhfT3ZoYlZHbHlWN2JlX1hoeDR3UmJMU0c?oc=5","date":"2023-08-01","type":"deal","source":"Nasdaq","summary":"Mundipharma International Corporation Limited, Mundipharma Medical Company, and Acrotech Biopharma Inc. Enter Agreement to Transfer License of FOLOTYN® (Pralatrexate) in China to CASI Pharmaceuticals ","headline":"Mundipharma International Corporation Limited, Mundipharma Medical Company, and Acrotech Biopharma Inc. Enter Agreement ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiggFBVV95cUxOSUFURDJOc21GU2FhanktU1FMTkM4T2M2ei1QSWpUTVdaT3ZkMktfUTdyT0FCSkd0dmtsVzIxTWQycnQ0VUktdkRublRSNjdtSy1tNDFlTUFKNFJUbFFreUU5V1BoVG5hSEpYRHc3c2ItS1dtR1FYdVNYWjNvck1sMnJR?oc=5","date":"2023-06-26","type":"deal","source":"Pharmaceutical Technology","summary":"iNova to acquire Mundipharma’s consumer healthcare brands - Pharmaceutical Technology","headline":"iNova to acquire Mundipharma’s consumer healthcare brands","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisgFBVV95cUxNQWN2dFhaNEI3dDRQcEtvd1dvWnVzLU9MekhZWWlrUWRndHZNU0ZsaTFROUFNU1JmVzIzUV9SV2RVNnF0SldoSzYyZUZkV3pZZ0ZEd1FrSWxMTng1d19pT0QwQ0VQUnhGdk80T2NhNzNtS1RqTmZVN0JoRnI2eU9ablhZc1A2ak5Jdk12eUxjTDJNcjdWNC02b0VmM3RBMmZaLVo1bTdOUHc2Ymx1NkZXR0Fn?oc=5","date":"2023-06-26","type":"deal","source":"Bloomberg.com","summary":"TPG-Backed Inova Agrees to Acquire Mundipharma’s OTC Business - Bloomberg.com","headline":"TPG-Backed Inova Agrees to Acquire Mundipharma’s OTC Business","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitAFBVV95cUxOZGR0LW45Nl9ZblB1ZnlpNDBKUng1ajNkdzBKZFFIOFFmM3VJNUowelp5Qmk5XzR5VGkxTjFxYk9nYVFSWUpYTjFFZFhpQ003SGlUVEM0V193ZFpDRWxSak8tQWZfMkU2bTdPQjBzRUNoaEowRFdKczIxUUxlYzJfX21Fd2dJR1ExRUtfbVVEMUFhbUE4M21RRmx2WkN0OC1GV3ZWcG14OFpaV1pBQzNJaVNhdVI?oc=5","date":"2019-12-15","type":"pipeline","source":"WGBH","summary":"Purdue Pharma’s Foreign Affiliate Now Selling Overdose Cure - WGBH","headline":"Purdue Pharma’s Foreign Affiliate Now Selling Overdose Cure","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimgJBVV95cUxPSVFJZjFSTkYxSW5JejVPTTNXbzFvVlhzaDZ5N0gxaUdxZ2prRFlxbTQ4Z0hzN1JCcGcwX2hEWjdycjFGMG9KYXIxMF9ERms4blVJQURvMmlUNzYxcTlyMkF1TDRlVkJZSTcyT0J4OTRmeTZiUm0yWF85dFhmMjVpLW8xQ0lSdHl1NTJsem92dG9USWJiMzkwUGVxY2NiV1k5bFJWbzlBWWJTd19WVmVFcThDSHlEc1hXSjFFYVU5TWZxb3RoX0VDU29EeE1iMXNxQ0JFcW5oR1BHd3psR2l2YXpiSzZ6elA4ME9Mc2FINDVwTWlYZTkzNU9aQzF0QlFhVW5VcERRM3IxTkNUdmIwRVZQWUpCT1BUSVE?oc=5","date":"2016-05-15","type":"deal","source":"PR Newswire","summary":"Mundipharma and Purdue Pharma Expand Pain Pipeline with New Deal for First-in-Class Sigma-1 Antagonist (S1A or MR309/E-52862) from ESTEVE - PR Newswire","headline":"Mundipharma and Purdue Pharma Expand Pain Pipeline with New Deal for First-in-Class Sigma-1 Antagonist (S1A or MR309/E-5","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_3":1},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}